Teva Announces Collaboration to Commercialize Formycon's Biosimilar Candidate to Eylea(R) (aflibercept) in major parts of Europe and in Israel

Source :: Thomson Reuters ONE. January 13, 2025
Publication Year :: 2025
Abstract: (GLOBE NEWSWIRE via COMTEX) -- - Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea(R)1 - Agreement builds on the proven and [...]

Subjects :: Teva Pharmaceutical Industries Ltd.
Business, international
Eylea (Medication)

Tools